Clinical trials
Lung cancer clinical trials
Cancer that begins in the lungs, often linked to smoking but also affecting non-smokers. We’re tracking 2,009 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05144698RecruitingPhase 1/Phase 2
RAPA-201 cell therapy for certain advanced lung and head cancers
This Phase 1/2 trial tests RAPA-201, a personalized immune cell treatment made from your own T cells, for advanced solid tumors. It may help people whose cancer has come back after standard treatment and after an anti–PD-1/PD-L1 antibody.
Hackensack, New JerseyAges 18 years+ - NCT06605534Recruiting
Lung cancer screening study for current and past smokers
This study uses the emergency department to offer lung cancer screening to people who smoke or recently quit. It aims to catch lung cancer early, when it's easier to treat.
Brick, New JerseyAges 50–80 - NCT06596915RecruitingPhase 1
BA1302 for advanced solid tumors
This trial tests a new drug, BA1302, for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if BA1302 is safe and effective.
BeijingAges 18 years+ - NCT05557487Recruiting
Real-world low-dose CT screening for people at high lung risk
This study looks at how people at high risk for lung cancer use low-dose CT scans in real life, and what outcomes happen over time. It may help confirm which groups benefit most from regular screening and support safer screening decisions.
Taichung, TaiwanAges 20–80 - NCT06303505RecruitingPhase 1/Phase 2
TUB-040 for advanced ovarian or lung cancer after standard treatments fail
This study tests a new drug called TUB-040 for people with ovarian cancer that has stopped responding to platinum chemotherapy, or with a type of lung cancer that has returned or spread. The drug is designed to target cancer cells and deliver a powerful anti-cancer agent directly to them, potentially slowing the disease.
Birmingham, AlabamaAges 18 years+ - NCT06150664RecruitingPhase 1
Study of CTX-8371 for advanced cancers no longer helped by standard therapy
This trial tests a new drug called CTX-8371 for people with advanced cancers (melanoma, head and neck, lung, triple-negative breast, or Hodgkin lymphoma) that have stopped responding to standard treatments, especially immunotherapy. It is a first-in-human study, meaning doctors are learning if the drug is safe and how well it works.
Margate, FloridaAges 18 years+ - NCT03467360RecruitingPhase 1
Adding an acetazolamide-type drug to lung cancer radiation and drugs
This Phase 1 trial tests whether blocking an enzyme (with an acetazolamide-like medicine) can be safely combined with standard treatment for small cell lung cancer that has not spread. The goal is to see if the treatment can be given safely and to learn early signs of benefit.
NiceAges 18 years+ - NCT03953144RecruitingPhase 1/Phase 2
3D lung surgery planning with a dye to find tumors
This trial tests a new way to plan and guide lung cancer surgery using a special dye that shows the tumor area during the operation. It may help surgeons remove the cancer more accurately while targeting only a small section of lung for certain early-stage patients.
Hamilton, OntarioAges 18 years+ - NCT03340506RecruitingPhase 4
Follow-on treatment study for dabrafenib and trametinib
This study lets people who finished a prior dabrafenib/trametinib trial (sponsored by Novartis or former GSK) continue those medicines if the study doctor thinks it will help. It mainly focuses on ongoing treatment benefit rather than testing a new drug.
Scottsdale, ArizonaAges 18–100 - NCT02984761Recruiting
Surgery vs focused radiation for early lung cancer
This trial compares two ways to treat early-stage lung cancer: surgery or a precise type of radiation called stereotactic radiotherapy. It aims to find out which approach works best for people whose cancer is small and has not spread.
Long Beach, CaliforniaAges 18 years+ - NCT07675967Recruiting
Blood Cell Changes During Cancer Treatment
This study is for people with solid tumors who are about to start chemotherapy or radiation. It looks at how these treatments affect blood cells and may help doctors understand changes in blood health over time.
Boston, MassachusettsAges 18 years+ - NCT05652686RecruitingPhase 1/Phase 2
Studying PT217 for neuroendocrine cancers
This trial tests a new drug called Peluntamig (PT217) for people with certain types of neuroendocrine cancers, like small cell lung cancer. It aims to see if the drug can help when standard treatments stop working or aren't an option.
Duarte, CaliforniaAges 18 years+ - NCT07801508RecruitingPhase 1
Trial of a new imaging agent for people with advanced solid tumors
This trial tests a radioactive imaging agent that may help doctors see tumors more clearly using a special scan. It is designed for adults with certain breast, lung, or stomach cancers that have spread.
Darlinghurst, New South WalesAges 18 years+ - NCT04451473Recruiting
Compare recovery programs after lung surgery
This trial compares two ways of helping patients recover after lung surgery: a “enhanced recovery” plan versus standard care. It may help your team find a recovery approach that improves comfort and recovery after surgery for certain lung problems.
Jinan, ShandongAges 18–85 - NCT07106827RecruitingPhase 1
Study of a new drug for advanced or resistant solid tumors
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
Chengdu, SichuanAges 18 years+ - NCT07223424RecruitingPhase 2
Patient preference study: shot vs infusion for immunotherapy
This study compares two ways to take immunotherapy drugs (nivolumab or pembrolizumab): as a shot under the skin (subcutaneous) versus an infusion into a vein (intravenous). It looks at which method patients prefer and is for people with certain advanced cancers where these drugs are already approved.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07705334RecruitingPhase 1
Study of SHY-ONC6 for advanced solid tumors
This trial tests a new drug called SHY-ONC6 that targets and breaks down cancer cells. It's for people with advanced solid tumors that haven't responded to standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT06605404Recruiting
Pan-tumor study of a blood test after cancer surgery
This study is testing a new blood test that looks for leftover cancer cells after surgery. It is for people with different types of solid tumors who are planning to have surgery to cure their cancer. The goal is to see if the test can help guide future treatment decisions.
Birmingham, AlabamaAges 18 years+ - NCT06114108Recruiting
Adding local treatment to drug therapy for stage IV lung cancer
This trial compares continuing drug therapy alone versus adding local treatments (surgery or radiation) for people with stage IV lung cancer that has responded to initial treatment but still has a few remaining spots (oligometastatic). The goal is to see if targeting those spots with local therapy helps control the cancer longer.
AarauAges 18 years+ - NCT06638554Recruiting
Using video visits to help people get screened for lung cancer
This trial tests whether telehealth (video visits) can help more people get screened for lung cancer. It may be a good fit if you are between 50 and 80, have a history of smoking, and have not had a lung cancer screening in the last two years.
Philadelphia, PennsylvaniaAges 50–80 - NCT06529822RecruitingPhase 1
Personalized cancer vaccine for solid tumors with residual disease
This trial tests a personalized cancer vaccine designed to help your immune system fight any remaining cancer cells after surgery. It is for people with certain solid tumors—like bladder, stomach, melanoma, or lung cancer—that show signs of disease through a blood test.
Orlando, FloridaAges 18 years+ - NCT07777614RecruitingPhase 2
Higher-dose lung radiation for early-stage lung cancer or a single lung tumor
This trial tests a higher-dose radiation treatment for lung cancer or a single tumor in the lung. It is designed for people who cannot have surgery or prefer not to, and whose tumor is near the chest wall making standard radiation difficult.
DublinAges 18 years+ - NCT07855965RecruitingPhase 2
Ablation with immunotherapy and chemo before lung cancer surgery
This study tests a new approach for people with early-stage lung cancer that can be removed with surgery. Before surgery, patients receive a treatment called cryo-thermal ablation to freeze and heat the tumor, along with an immunotherapy drug (toripalimab) and chemotherapy. The goal is to see if this combination shrinks tumors and improves outcomes after surgery.
Chengdu, SichuanAges 18–80 - NCT02511288Recruiting
Blood tests to monitor advanced lung cancer during care
This study checks whether “liquid biopsies” (blood tests) can help monitor advanced non-small-cell lung cancer. It looks at different patient groups based on timing and tumor features, aiming to make cancer tracking easier and less invasive.
AnnecyAges 18 years+
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer?
- Yes. Clin2 currently lists 2,009 recruiting lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.